Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
Puzanov I, Sosman J, Santoro A, Saif MW, Goff L, Dy GK, Zucali P, Means-Powell JA, Ma WW, Simonelli M, Martell R, Chai F, Lamar M, Savage RE, Schwartz B, Adjei AA. Puzanov I, et al. Among authors: ma ww. Invest New Drugs. 2015 Feb;33(1):159-68. doi: 10.1007/s10637-014-0167-5. Epub 2014 Oct 8. Invest New Drugs. 2015. PMID: 25294187 Free PMC article. Clinical Trial.
Novel agents on the horizon for cancer therapy.
Ma WW, Adjei AA. Ma WW, et al. CA Cancer J Clin. 2009 Mar-Apr;59(2):111-37. doi: 10.3322/caac.20003. CA Cancer J Clin. 2009. PMID: 19278961 Free article. Review.
Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Ma WW, Messersmith WA, Dy GK, Weekes CD, Whitworth A, Ren C, Maniar M, Wilhelm F, Eckhardt SG, Adjei AA, Jimeno A. Ma WW, et al. Clin Cancer Res. 2012 Apr 1;18(7):2048-55. doi: 10.1158/1078-0432.CCR-11-2813. Epub 2012 Feb 14. Clin Cancer Res. 2012. PMID: 22338014 Clinical Trial.
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
Infante JR, Novello S, Ma WW, Dy GK, Bendell JC, Huff A, Wang Q, Suttle AB, Allen R, Xu CF, Ottesen LH, Burris HA 3rd, Adjei AA. Infante JR, et al. Among authors: ma ww. Invest New Drugs. 2013 Aug;31(4):927-36. doi: 10.1007/s10637-012-9900-0. Epub 2012 Nov 22. Invest New Drugs. 2013. PMID: 23179337 Clinical Trial.
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
Weekes CD, Von Hoff DD, Adjei AA, Leffingwell DP, Eckhardt SG, Gore L, Lewis KD, Weiss GJ, Ramanathan RK, Dy GK, Ma WW, Sheedy B, Iverson C, Miner JN, Shen Z, Yeh LT, Dubowy RL, Jeffers M, Rajagopalan P, Clendeninn NJ. Weekes CD, et al. Among authors: ma ww. Clin Cancer Res. 2013 Mar 1;19(5):1232-43. doi: 10.1158/1078-0432.CCR-12-3529. Epub 2013 Feb 22. Clin Cancer Res. 2013. PMID: 23434733 Clinical Trial.
Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours.
Devriese LA, Koch KM, Mergui-Roelvink M, Matthys GM, Ma WW, Robidoux A, Stephenson JJ, Chu QS, Orford KW, Cartee L, Botbyl J, Arya N, Schellens JH. Devriese LA, et al. Among authors: ma ww. Invest New Drugs. 2014 Jun;32(3):481-8. doi: 10.1007/s10637-013-0055-4. Epub 2013 Dec 19. Invest New Drugs. 2014. PMID: 24346280 Clinical Trial.
256 results